Access the full text.
Sign up today, get DeepDyve free for 14 days.
R. Robbins, A. Driedger, J. Magner (2006)
Recombinant human thyrotropin-assisted radioiodine therapy for patients with metastatic thyroid cancer who could not elevate endogenous thyrotropin or be withdrawn from thyroxine.Thyroid : official journal of the American Thyroid Association, 16 11
Syed Hussain, M. Zaman, S. Malik, N. Ram, A. Asghar, U. Rabbani, N. Aftab, N. Islam (2014)
Preablation Stimulated Thyroglobulin/TSH Ratio as a Predictor of Successful I131Remnant Ablation in Patients with Differentiated Thyroid Cancer following Total ThyroidectomyJournal of Thyroid Research, 2014
Kwanhoon Jo, D. Lim (2018)
Clinical implications of anti-thyroglobulin antibody measurement before surgery in thyroid cancerThe Korean Journal of Internal Medicine, 33
J. Nagarajah, M. Janssen, P. Hetkamp, W. Jentzen (2017)
Iodine Symporter Targeting with 124I/131I TheranosticsThe Journal of Nuclear Medicine, 58
N. Fleeman, R. Houten, Marty Chaplin, S. Beale, A. Boland, Y. Dundar, J. Greenhalgh, Rui Duarte, A. Shenoy (2019)
A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodineBMC Cancer, 19
P. Ladenson (2000)
Recombinant thyrotropin versus thyroid hormone withdrawal in evaluating patients with thyroid carcinoma.Seminars in nuclear medicine, 30 2
A. Khoo, L. Fong, Fadzilah Hamzah (2018)
A Review of TENIS Syndrome in Hospital Pulau PinangIndian Journal of Nuclear Medicine : IJNM : The Official Journal of the Society of Nuclear Medicine, India, 33
M. Schlumberger, M. Tahara, L. Wirth, B. Robinson, M. Brose, R. Elisei, M. Habra, K. Newbold, M. Shah, A. Hoff, A. Gianoukakis, N. Kiyota, Matthew Taylor, Sung-Bae Kim, M. Krzyzanowska, C. Dutcus, B. Heras, Junming Zhu, S. Sherman (2015)
Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.The New England journal of medicine, 372 7
R. Tuttle, B. Haugen, N. Perrier (2017)
Updated American Joint Committee on Cancer/Tumor-Node-Metastasis Staging System for Differentiated and Anaplastic Thyroid Cancer (Eighth Edition): What Changed and Why?Thyroid : official journal of the American Thyroid Association, 27 6
S. Basu, M. Dandekar, A. Joshi, A. D'cruz (2015)
Defining a rational step-care algorithm for managing thyroid carcinoma patients with elevated thyroglobulin and negative on radioiodine scintigraphy (TENIS): considerations and challenges towards developing an appropriate roadmapEuropean Journal of Nuclear Medicine and Molecular Imaging, 42
M. Lubberink, S. Fatah, B. Brans, O. Hoekstra, G. Teule (2008)
The role of (124)I-PET in diagnosis and treatment of thyroid carcinoma.The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of..., 52 1
G. Rendl, B. Sipos, A. Becherer, S. Sorko, C. Trummer, M. Raderer, W. Hitzl, M. Ardelt, H. Gallowitsch, C. Pirich (2020)
Real-World Data for Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer (RELEVANT): A Retrospective Multicentric Analysis of Clinical Practice in AustriaInternational Journal of Endocrinology, 2020
Nai-wei Sheu, He‐Jiun Jiang, Che‐Wei Wu, F. Chiang, H. Chiou, P. Hsiao (2019)
Lenvatinib complementary with radioiodine therapy for patients with advanced differentiated thyroid carcinoma: case reports and literature reviewWorld Journal of Surgical Oncology, 17
H. Phan, P. Jager, A. Paans, J. Plukker, M. Sturkenboom, Willem Sluiter, B. Wolffenbuttel, R. Dierckx, T. Links (2007)
The diagnostic value of 124I-PET in patients with differentiated thyroid cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 35
P. Rosário, Gabriela Mourão, M. Calsolari (2015)
Is Stimulated Thyroglobulin Necessary after Ablation in All Patients with Papillary Thyroid Carcinoma and Basal Thyroglobulin Detectable by a Second-Generation Assay?International Journal of Endocrinology, 2015
Y. Krausz, B. Uziely, R. Nesher, R. Chisin, B. Glaser (2001)
Recombinant thyroid-stimulating hormone in differentiated thyroid cancer.The Israel Medical Association journal : IMAJ, 3 11
C. Spencer (2011)
Clinical review: Clinical utility of thyroglobulin antibody (TgAb) measurements for patients with differentiated thyroid cancers (DTC).The Journal of clinical endocrinology and metabolism, 96 12
Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations
Differentiated thyroid cancer is an indolent cancer with an excellent prognosis when treated adequately. The treatment algorithm is well established and standardized. Surgery followed by radio-iodine treatment has stood the test of time. In the last decade, the paradigm has slightly shifted with newer diagnostic approaches like stimulated thyroglobulin and anti-thyroglobulin antibodies impacting the treatment decisions. The diagnostic whole body radio-iodine scan has also got innovated with the introduction of r-TSH injection protocol wherein the scan is performed while the patient is on thyroxine thereby minimizing patient discomfort. The new RISK-based classification system has resulted in altered treatment algorithms by sub dividing patients into low-, intermediate-, and high-risk groups. There has also been identification of TWO new class of thyroid cancer patients—radio-iodine-resistant thyroid cancer and TENIS syndrome (thyroglobulin elevated negative iodine scan) patients. Both these groups posed major challenge to treatment and this resulted in incorporation of TARGETED THERAPY based on the mutations that occur in these TWO groups of patients. The introduction of Sorafenib and Lenvatinib has made significant impact on progression-free and overall survival of these patients. The introduction of THYROPET (124-I PET scan) is gaining momentum as an alternative to 123/131-I scans due to high-resolution images on PET scan increasing the detection sensitivity. All the above factors have resulted in paradigm shift in the management of differentiated thyroid cancer patients.
Indian Journal of Surgical Oncology – Springer Journals
Published: Mar 1, 2022
Keywords: Stimulated thyroglobulin (Tg); Recombinant TSH; TENIS syndrome; Targeted therapy
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.